Free Trial
OTCMKTS:BICX

Biocorrx 5/15/2026 Earnings Report

Biocorrx logo
$0.49 0.00 (0.00%)
As of 05/15/2026 01:55 PM Eastern

Biocorrx EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Biocorrx Revenue Results

Actual Revenue
$0.22 million
Expected Revenue
$0.22 million
Beat/Miss
Missed by -$5.00 thousand
YoY Revenue Growth
N/A

Biocorrx Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Biocorrx Earnings Headlines

BioCorRx Inc.
Why Elon just bought a power plant (Ticker inside)
Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer without equipment that typically has a 2-year lead time — so he shipped an entire industrial power plant across the Atlantic Ocean. One small company holds a $1.5 billion backlog for the exact hardware Musk's 'Colossus' site needs to scale. Wall Street still prices it like a sleepy industrial stock, but a June IPO could change that fast.tc pixel
See More Biocorrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email.

About Biocorrx

Biocorrx (OTCMKTS:BICX), through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

View Biocorrx Profile